Literature DB >> 11285447

[Traumatic superior orbital fissure syndrome: report of 4 cases and review of literature].

L Giaoui1, R Lockhart, F Lafitte, B Girard, L Chikani, G Fleuridas, J C Bertrand, F Guilbert.   

Abstract

PURPOSE: The authors retrospectively analyzed four cases of posttraumatic superior orbital fissure syndrome and reviewed the literature.
METHOD: Four patients (three male and one female) were followed for this complication in the department from october 1995 to december 1996.
RESULTS: The mean age was 31 years, the median follow-up was 8 month. Computed tomography showed involvement of the superior orbital fissure but no in three patients, in the fourth. The treatment consisted of osteosynthesis of craniofacial fracture in three patients and corticosteroid therapy in the last one. All patients presented partial recuperation of external ophthalmoplegia and ptosis. Twelve months after the traumatism, one patient underwent surgery for persistant ptosis and diplopia.
CONCLUSION: The superior orbital fissure syndrome is an exceptional complication of orbital traumas. Partial recuperation of the neuro-ophthalmologic function usually occurs within a period of several months.

Entities:  

Mesh:

Year:  2001        PMID: 11285447

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  3 in total

1.  Traumatic superior orbital fissure syndrome: current management.

Authors:  Chien-Tzung Chen; Yu-Ray Chen
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2010-03

2.  Neuronavigation-guided endoscopic decompression of superior orbital fissure fracture: case report and literature review.

Authors:  Jaime Gasco; Kristopher Hooten; Ryan W Ridley; Leonardo Rangel-Castilla; Amole Adewumi; Haring J Nauta; Vicente A Resto
Journal:  Skull Base       Date:  2009-05

3.  An unusual case of total ophthalmoplegia.

Authors:  Ravindra Kumar Chowdhury; Navnit Gupta; Krishna Charan Padhy
Journal:  Indian J Ophthalmol       Date:  2009 Sep-Oct       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.